Digestive Diseases and Sciences

, Volume 63, Issue 2, pp 529–532 | Cite as

Occurrence of Jaundice Following Simultaneous Ursodeoxycholic Acid Cessation and Obeticholic Acid Initiation

Case Report


Ursodeoxycholic acid Obeticholic acid Primary biliary cholangitis Jaundice 


Author’s contribution

All authors have worked together in collecting data, reviewing medical literature, and writing up of this manuscript.

Compliance with ethical standards

Conflict of interest

The authors Abdul Nadir M.D., Gerard Quigley N.P., and Mustafa Al Ani M.D. certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.

Informed consent

Informed consent was obtained from the patient.


  1. 1.
    Hirschfield GM, Mason A, Luketic V, et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology. 2015;148:751–761.CrossRefPubMedGoogle Scholar
  2. 2.
    Zein CO, Angulo P, Lindor KD. When is liver biopsy needed in the diagnosis of primary biliary cirrhosis? Clin Gastroenterol Hepatol. 2003;1:89–95.CrossRefPubMedGoogle Scholar
  3. 3.
    Tan S, Ayutyanont N, Bhattarai B, et al. Clinical characteristics of antimitochondrial antibody-positive patients at a safety net health care system in Arizona. BMJ Open Gastroenterol. 2017;4:e000158.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Lindor KD, Gershwin ME, Poupon R, et al. Primary biliary cirrhosis. Hepatology. 2009;50:291–308.CrossRefPubMedGoogle Scholar
  5. 5.
    Silveira MG, Lindor KD. Treatment of primary biliary cirrhosis: therapy with choleretic and immunosuppressive agents. Clin Liver Dis. 2008;12:425–443.CrossRefPubMedGoogle Scholar
  6. 6.
    Wunsch E, Trottier J, Milkiewicz M, et al. Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis. Hepatology. 2014;60:931–940.CrossRefPubMedGoogle Scholar
  7. 7.
    Food and Drug Administration. FDA Drug Safety Communication: FDA warns about serious liver injury with Ocaliva (obeticholic acid) for rare chronic liver disease. September 21 2017.Google Scholar
  8. 8.
    Kowdley KV, Jones D, Luketic V, et al. An international study evaluating the farnesoid X receptor agonist obeticholic acid as monotherapy in PBC. J Hepatol. 2011;54:S13.CrossRefGoogle Scholar
  9. 9.
    Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, nonalcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015;385:956–965.CrossRefPubMedGoogle Scholar
  10. 10.
    Nevens F, Andreone P, Mazzella G, et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med. 2016;375:631–643.CrossRefPubMedGoogle Scholar
  11. 11.
    Spacek LA, Solga SF. Obeticholic acid in primary biliary cholangitis. N Engl J Med. 2016;375:e41.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Maricopa Medical CenterPhoenixUSA

Personalised recommendations